Facebook
Twitter
LinkedIn
ForwardASTRO’s First Evidence-Based Clinical Practice Guidelines on Radiation Therapy for Primary Liver Cancers - 2021 Annual Meeting
This cased-based panel focuses on the guideline recommendations and evidentiary basis for EBRT for HCC and IHC. In ASTRO’s first primary liver cancers guideline, recommendations address the: 1) role of EBRT in the definitive/non-transplant setting in HCC and IHC; 2) role of EBRT in the neoadjuvant setting prior to surgical resection or OLT for HCC; and 3) recommended techniques, dose-fractionation regimens, and OAR dose constraints.
In addition to ASTRO, the guideline task force included multidisciplinary representation from the American Society of Clinical Oncology and the Society of Surgical Oncology. The ASTRO guideline development process and the systemic review parameters for this guideline is also briefly presented. To make the course more interactive and to frame the recommendations addressed in this guideline, speakers present case conferences to solidify the understanding of the more complex and controversial topics. Speakers ask the audience to respond to the SA-CME questions to confirm their comprehension of the guideline information from the presentation.
This activity is available from March 1, 2022, through 11:59 p.m. Eastern time on February 28, 2025.
This activity was originally recorded at ASTRO’s 2021 Annual Meeting, October 24-27th.
Target Audience
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, medical oncologists, surgeons, radiation physicists, radiation therapists, radiation dosimetrists, specialists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify and describe the clinically relevant clinical trials and data related to the use of EBRT for HCC and IHC for multiple clinical settings.
- Apply new evidence-based guideline recommendations to clinical practice.
- Discuss the limitations and knowledge gaps of EBRT and emerging technologies and treatments for HCC and IHC.
- Higinia Rosa Rosa Cardenes, MD, PhD, Weill Cornell Medicine has no financial relationships with a commercial interest.
- Aisling S. Barry, MD, Radiation Medicine Program, University Health Network and Princess Margaret Cancer Centre has no financial relationships with a commercial interest.
- Foster D. Lasley, MD, GenesisCare has investment interest from Book: "Basic Radiotherapy Physics and Biology": Royalty and from Book: "Basic Radiotherapy Physics and Biology 2nd": Royalty.
- Eugene J Koay, MD, PhD, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center receives compensation from General Electric, MD Anderson Cancer Center, NIH and Phillips. Dr. Lasley has investment interest from Taylor and Francis LLC.
- Dawn Owen, MD, PhD, Department of Radiation Oncology, Mayo Clinic receives compensation from Mayo Clinic and NIH P01 Grant.
- Christopher L. Hallemeier, MD, Mayo Clinic, Department of Radiation Oncology and Department of Radiation Oncology, Mayo Clinic receives compensation from Mayo Clinic.
- Smith Apisarnthanarax, MD, University of Washington Department of Radiation Oncology has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
Nonmember: $105
Member: $55
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until February 28, 2025, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.